These data raise a compelling rationale for concomitant use of CSF-1 and anti–P selectin antibody in SCD, because it could serve dual functions: mitigating vaso-occlusion by elevating circulating PMo numbers while simultaneously bolstering tissue-resident macrophage populations to protect against organ damage. This evidence concerns the gene CSF1 and Schnyder corneal dystrophy.